Sorry, Santa: AbbVie Shows ‘Naughty’ Can Be Profitably Nice (For Some)

AbbVie's " patent thicket " strategy and aggressive drug pricing tactics have made it a prominent example of pharma finagling. But the company isn't the only beneficiary.
Source: Forbes.com Healthcare News - Category: Pharmaceuticals Authors: Tags: Healthcare /healthcare Innovation /innovation business pharma standard Source Type: news